Compare iShares MSCI Hong Kong ETF (EWH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI Hong Kong ETF trades at $22.46, while Twist Bioscience Corp trades at $124.64 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $124.88 |
52-Week Low | $20.66 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.45, down 1.54% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights the Hang Seng Index's rebound and potential golden cross formation, driven by technology stock recoveries. The ETF shows no available fundamental ratios in the provided data, but tracks Hong Kong equities, with a dividend scheduled for June 2026.
Outlook hinges on Hong Kong market performance and tech sector momentum. Risks include Asian market volatility and geopolitical factors. Analyst sentiment is mixed, with some bullish on Hong Kong over Korea, while technicals suggest caution near support at $22.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
